Sinecatechins
As of the edition of 20 October 2026, Sinecatechins is a drug: marketed, first approved in 2006 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2006
- Kind
- Unknown
- Brand name
- Veregen
- First approved
- 31 October 2006 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- ANI Pharmaceuticals
- Registered trials
- 28, 8 stopped early
- Disease areas
- Cancer; Urinary and reproductive; Immune system; Infections; Skin and connective tissue; Lungs and airways
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 |
| Phase 2 | 17 | 9 | 1 | 7 |
| Phase 3 | 3 | 3 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| MediGene | Earlier holder and Lead sponsor of trials | 2003 to now |
| ANI Pharmaceuticals | Acquired holder | 2021 to now |